Telephone: 617-724-9619; Fax: 617-726-0561
Cancer Stem Cells
Version of Record online: 8 OCT 2009
Copyright © 2009 AlphaMed Press
Volume 27, Issue 12, pages 2875–2883, December 2009
How to Cite
Curley, M. D., Therrien, V. A., Cummings, C. L., Sergent, P. A., Koulouris, C. R., Friel, A. M., Roberts, D. J., Seiden, M. V., Scadden, D. T., Rueda, B. R. and Foster, R. (2009), CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer. STEM CELLS, 27: 2875–2883. doi: 10.1002/stem.236
Author contributions: M.D.C.: Collection and assembly of data, data analysis and interpretation, manuscript writing; V.A.T. and C.L.C.: Collection and assembly of data; P.A.S.: Provision of study material; C.R.K.: Provision of study material; A.M.F.: Collection and assembly of data, data analysis and interpretation; D.J.R.: Data analysis and interpretation; M.V.S.: Conception and design, financial support, provision of study material or patients; D.T.S.: Financial support, data analysis and interpretation; B.R.R.: Conception and design, financial support, provision of study material and patients, data analysis and interpretation, manuscript writing; R.F.: Conception and design, financial support, provision of study material or patients, data analysis and interpretation, manuscript writing, final approval of manuscript.
First published online in STEM CELLS EXPRESS October 8, 2009.
Disclosure of potential conflicts of interest is found at the end of this article.
- Issue online: 14 DEC 2009
- Version of Record online: 8 OCT 2009
- Accepted manuscript online: 8 OCT 2009 12:00AM EST
- Manuscript Accepted: 24 SEP 2009
- Manuscript Received: 15 JUL 2009
- Dana Farber/Harvard Cancer Center Ovarian SPORE
- Marsha Rivkin Center for Ovarian Cancer Research
- The Julie Fund
- Advanced Medical Research Foundation
- Ovarian Cancer Research Fund
- Vincent Memorial Research Fund
- Ovarian Cancer and Education Awareness Network
- Robert Lynn v. d. Luft and Christa v. d. Luft
Additional supporting information available online.
|STEM_236_sm_suppinfofigure1.tif||39965K||Supplementary Figure 1. Hematoxylin and eosin stained sections of primary serous (SOC1-6), clear cell (COC1-2) and endometrioid (EnOC1) tumors and their respective first transplant tumors. First transplant (xenograft) tumors were generated by s.c. injection of 1x106 bulk primary tumors cells into NOD/SCID mice. The histology of the parent primary tumor is maintained by the xenografted tumors formed in vivo. Magnification, 20X; scale bar, 50μm.|
|STEM_236_sm_suppinfofigure2.tif||21684K||Supplementary Figure 2. Hematoxylin and eosin stained sections of serially transplanted serous (SOC1) and clear cell (COC1) tumors, which show that the histology of the tumors is retained over multiple transplants in NOD/SCID mice. Magnification, 20X; scale bar, 50μm.|
|STEM_236_sm_suppinfotable1.doc||45K||Supplementary Table 1. Patient age and tumor subtype information|
|STEM_236_sm_suppinfotable2.doc||45K||Supplementary Table 2. In vivo tumor formation capacity of serially-diluted human primary ovarian serous tumor cells|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.